{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:25:15Z","timestamp":1793982315803,"version":"4.8.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in immune-mediated and hematologic diseases, but its efficacy may be limited by the development of anti-rituximab antibodies (ADAs). This narrative review summarizes current evidence on the incidence, detection, and clinical implications of ADAs in nephropathies and other immune-mediated disorders. ADA prevalence varies markedly across diseases and is influenced by assay methodology, timing of testing, and patient immune background. Although not all ADAs are clinically relevant, their presence has been associated with lower rituximab levels, earlier B-cell repopulation, reduced clinical\/immunological remission, more frequent relapses, and hypersensitivity reactions. Overall, ADAs represent an underrecognized factor that may affect rituximab efficacy and safety, supporting the need for improved monitoring and more personalized therapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1896560","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:35:20Z","timestamp":1789464920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review"],"prefix":"10.3389","volume":"17","author":[{"given":"Marco","family":"Allinovi","sequence":"first","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Lomi","sequence":"additional","affiliation":[{"name":"SOC Nefrologia e Dialisi, Ospedale Santa Maria Annunziata di Firenze","place":["Firenze, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Accinno","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Teisseyre","sequence":"additional","affiliation":[{"name":"French Reference Center for Rare Diseases, Idiopathic Nephrotic Syndrome and Membranous Nephropathy, Nice University Hospital, Universit\u00e9 C\u00f4te d\u2019Azur","place":["Nice, France"]},{"name":"Immunology Laboratory, Nice University Hospital, Universit\u00e9 C\u00f4te d\u2019Azur","place":["Nice, France"]},{"name":"Institute for Research on Cancer and Aging (IRCAN), Universit\u00e9 C\u00f4te d\u2019Azur","place":["Nice, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Diomaiuti","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Madeo","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, San Jacopo Hospital","place":["Pistoia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Allegretta","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[{"name":"Immunoallergology Unit, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","article-title":"Mechanism of action of rituximab","volume":"12","author":"Maloney","year":"2001","journal-title":"Anti-Cancer Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint Bone Spine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.11.011","article-title":"Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology","volume":"222","author":"Sent\u00eds","year":"2017","journal-title":"Immunobiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201445","article-title":"Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation","volume":"72","author":"Van Schouwenburg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei075","article-title":"Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus","volume":"44","author":"Saito","year":"2005","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Multiple Sclerosis J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04629-w","article-title":"Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome","volume":"35","author":"Fujinaga","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ftira8","article-title":"Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases","volume":"40","author":"Oomen","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103690","DOI":"10.1016\/j.ekir.2025.11.015","article-title":"Obinutuzumab as a rescue therapy in anti-rituximab antibody-positive primary membranous nephropathy","volume":"11","author":"Liu","year":"2026","journal-title":"Kidney Int Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15177","article-title":"Rituximab\u2010induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti\u2010rituximab antibodies","volume":"184","author":"Vendramin","year":"2019","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05069-w","article-title":"Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome","volume":"37","author":"Bertrand","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-023-03076-w","article-title":"Real-life drug retention rate and safety of rituximab when treating rheumatic diseases: a single-centre Swiss retrospective cohort study","volume":"25","author":"Dumusc","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12916","article-title":"A phase I pharmacokinetics trial comparing PF\u201005280586 (A potential biosimilar) and rituximab in patients with active rheumatoid arthritis","volume":"82","author":"Cohen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3524-9","article-title":"Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83TM, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach","volume":"81","author":"Candelaria","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1770916","article-title":"Optimized RTX strategy plus structured glucocorticoid tapering for primary membranous nephropathy: a multicenter propensity score-matched cohort study","volume":"13","author":"Sun","year":"2026","journal-title":"Front Mol Biosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag137","article-title":"Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies","author":"Hartinger","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose\u2010escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.22046","article-title":"Long\u2010term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re\u2010treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0565-z","article-title":"A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Modern Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately\u2010to\u2010severely active systemic lupus erythematosus: the randomized, double\u2010blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open\u2010label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.08.006","article-title":"Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome","volume":"7","author":"Angeletti","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2794-7","article-title":"Development of antirituximab antibodies in children with nephrotic syndrome","volume":"29","author":"Ahn","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20250519-00431","article-title":"Association of anti-rituximab antibodies with relapse after therapy in children with frequently relapsing or steroid-dependent nephrotic syndrome","volume":"63","author":"Wang","year":"2025","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-026-07481-6","article-title":"The impact of anti-rituximab antibodies on rituximab efficacy in children with frequently relapsing or steroid-dependent nephrotic syndrome","author":"Wang","year":"2026","journal-title":"Pediatr Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00415-025-13161-6","article-title":"Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment","volume":"272","author":"H\u00e9raud","year":"2025","journal-title":"J Neurol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory b cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing\u2010remitting multiple sclerosis: A 72\u2010week, open\u2010label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double\u2010blind placebo\u2010controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamadermatol.2022.2149","article-title":"Evaluation of clinical relevance and biological effects of antirituximab antibodies in patients with pemphigus","volume":"158","author":"Lemieux","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-cd20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00398-7","article-title":"A randomized, double-blind, efficacy and safety study of pf-05280586 (a rituximab biosimilar) compared with rituximab reference product (Mabthera\u00ae) in subjects with previously untreated cd20-positive, low-tumor-burden follicular lymphoma (Ltb-fl)","volume":"34","author":"Sharman","year":"2020","journal-title":"BioDrugs"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00487-6","article-title":"Factors influencing infusion-related reactions following dosing of reference rituximab and pf-05280586, a rituximab biosimilar","volume":"35","author":"Courville","year":"2021","journal-title":"BioDrugs"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.10.019","article-title":"Rituximab serum concentrations and anti-rituximab antibodies during b-cell depletion therapy for myalgic encephalopathy\/chronic fatigue syndrome","volume":"41","author":"Rekeland","year":"2019","journal-title":"Clin Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double\u2010blind, placebo\u2010controlled, dose\u2010ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open\u2010label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of b-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0232-7","article-title":"Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar ct-p10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial","volume":"31","author":"Yoo","year":"2017","journal-title":"BioDrugs"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003348","article-title":"Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium","volume":"17","author":"H\u00e4ssler","year":"2020","journal-title":"PloS Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211281","article-title":"A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/acr.23771","article-title":"Safety and immunogenicity of rituximab biosimilar gp 2013 after switch from reference rituximab in patients with active rheumatoid arthritis","volume":"71","author":"Tony","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13075-024-03456-w","article-title":"Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (Drl_ri) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study","volume":"26","author":"Maharaj","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac024","article-title":"Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (Ultra-)low-dose rituximab","volume":"61","author":"Wientjes","year":"2022","journal-title":"Rheumatology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-07033-4","article-title":"Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies","volume":"41","author":"Parmentier","year":"2026","journal-title":"Pediatr Nephrol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","article-title":"Differential effect of drug interference in immunogenicity assays","volume":"372","author":"Hart","year":"2011","journal-title":"J Immunol Methods"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J Med Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.823174","article-title":"Structural characterization of the full-length anti-cd20 antibody rituximab","volume":"9","author":"Belviso","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1424610","article-title":"Development and characterization of an anti-rituximab monoclonal antibody panel","volume":"10","author":"Tada","year":"2018","journal-title":"mAbs"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2324836","article-title":"T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics","volume":"16","author":"Sun","year":"2024","journal-title":"mAbs"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-022-05612-3","article-title":"Anti-B cell strategy for complicated steroid-dependent nephrotic syndrome in children with antirituximab antibodies","volume":"37","author":"Fujinaga","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0061","article-title":"Antidrug antibody formation in oncology: clinical relevance and challenges","volume":"21","author":"Van Brummelen","year":"2016","journal-title":"Oncologist"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00500","article-title":"Characterization of cd4 t cell epitopes of infliximab and rituximab identified from healthy donors","volume":"8","author":"Hamze","year":"2017","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/antib9020022","article-title":"Principles of n-linked glycosylation variations of igg-based therapeutics: pharmacokinetic and functional considerations","volume":"9","author":"Boune","year":"2020","journal-title":"Antibodies"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28066","article-title":"Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation","volume":"119","author":"Edwards","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"key":"B85","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J Immunotoxicol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (Sabrina): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5405","article-title":"Cathepsin-dependent apoptosis triggered by supraoptimal activation of t lymphocytes: a possible mechanism of high dose tolerance","volume":"172","author":"Michallet","year":"2004","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000422","article-title":"A novel strategy to reduce the immunogenicity of biological therapies","volume":"185","author":"Somerfield","year":"2010","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195325","article-title":"Identification of HLA-DRB1 association to adalimumab immunogenicity","volume":"13","author":"Liu","year":"2018","journal-title":"PloS One"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"Hla-dqa1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab076.538","article-title":"P414 obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with inflammatory bowel disease","volume":"15","author":"Mahmoud","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag054","article-title":"Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy","author":"Wu","year":"2026","journal-title":"Nephrol Dialysis Transplant"},{"key":"B94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: An EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosis, assessment, and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0189-7","article-title":"Immunogenicity to biologics: mechanisms, prediction and reduction","volume":"60","author":"Sethu","year":"2012","journal-title":"Archivum Immunol Ther Experimentalis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1159\/000336839","article-title":"Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab","volume":"159","author":"Vultaggio","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1306648","article-title":"Adverse drug reactions after intravenous rituximab infusion are more common in hematologic Malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients","volume":"58","author":"D\u2019Arena","year":"2017","journal-title":"Leukemia Lymphoma"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.027","article-title":"Novel rituximab desensitization protocol increases safety of drug desensitization","volume":"129","author":"Sokol","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0445","article-title":"Rapid drug desensitization with rituximab in 24 cases: a single-center experience","volume":"29","author":"G\u00f6rg\u00fcl\u00fc","year":"2019","journal-title":"J Investigat Allergol Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.590991","article-title":"Mechanisms of drug desensitization: Not only mast cells","volume":"11","author":"Vultaggio","year":"2020","journal-title":"Front Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"12558","DOI":"10.1038\/s41598-021-91851-7","article-title":"Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis","volume":"11","author":"Vultaggio","year":"2021","journal-title":"Sci Rep"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.jaip.2019.12.040","article-title":"Desensitization modulates humoral and cellular immune response to infliximab in a patient with an immediate hypersensitivity reaction","volume":"8","author":"Vultaggio","year":"2020","journal-title":"J Allergy Clin Immunol: In Pract"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2019.9.e9","article-title":"Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type","volume":"9","author":"Gelincik","year":"2019","journal-title":"Asia Pac Allergy"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/all.14311","article-title":"Rapid drug desensitization for platinum\u2010based chemotherapy drugs significantly increases peripheral blood IL\u201010 levels","volume":"75","author":"T\u00fczer","year":"2020","journal-title":"Allergy"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti\u2010rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300647","article-title":"Cross-reactivity of antibodies to rituximab with other therapeutic anti-cd20 antibodies","volume":"212","author":"Rispens","year":"2024","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfag104","article-title":"Anti-obinutuzumab antibodies in primary membranous nephropathy","author":"Liu","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2013.835698","article-title":"Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics","volume":"6","author":"De Groot","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B112","article-title":"Prediction of immunogenicity for therapeutic proteins: state of the art","volume":"10","author":"De Groot","year":"2007","journal-title":"Curr Opin Drug Discov Dev"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:35:23Z","timestamp":1789464923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2026.1896560"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1896560","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1896560"}}